Post-market Surveillance Study of an Infant Formula Containing Moderately Hydrolyzed Protein and Low Lactose

Post-market Surveillance Study of an Infant Formula Containing Moderately Hydrolyzed Protein and Low Lactose: A Before-after Trial

The study is a before-after trial to evaluate whether the study formula containing moderately hydrolyzed protein and low lactose will be able to improve mild gastrointestinal disorders (MGDs) in infants. The study plans to recruit 90 infants between 7 days and 6 months old in Huantai Maternal and Child Health Care Hospital in Shandong Province and intervene for 14 consecutive days. On Day 0 (the time of enrolling group, but the intervention which infants recruited are asked to drink study formula begins on Day 1), Day 7, Day 14, Infant Gastrointestinal Symptoms Questionnaire-13 (IGSQ-13) is used to collect infants gastrointestinal comfort, related behaviors and other information.

Study Overview

• Status: Unknown
• Conditions: Gastrointestinal Dysfunction; Infant Nutrition Disorders
• Intervention / Treatment: Dietary supplement: Drink the study formula (NAN Comfort producted by Nestle Deutschland AG)

Detailed Description

Mild gastrointestinal disorders in infants belong to the category of functional gastrointestinal disorders. It refers that the infants fed with formula have mild digestive dysfunction that can not be explained by organic lesions or biochemical abnormalities, mainly including intestinal colic, spitting milk, diarrhea, constipation, etc. Mild gastrointestinal disorders are common in infants aged 0 to 1 year old. A study across 15 cities in China on the prevalence of common gastrointestinal disorders in infants shows that about 1/3 of the infants have one or more types of gastrointestinal disorders, among of which diarrhea and spitting milk are most common, and most of them occur within the age of 6 months. To solve this problem, a special kind of formulas for infants containing moderately hydrolyzed protein and low lactose has been developed, and our study formula is one of them. The study formula has been already marketed in China and passed the test hosted by the comprehensive testing center of the Chinese academy of inspection and quarantine, but whether it can significantly improve the mild gastrointestinal disorders in Chinese infants remains to be evaluated.

The purpose of the study is to evaluate whether the study formula containing moderately hydrolyzed protein and low lactose will be able to improve mild gastrointestinal disorders (MGDs) in infants. After informed consent, 90 infants between 7 days and 6 months old with mild gastrointestinal disorders are included and asked to drink the study formula for 14 consecutive days as intervention. On Day 0 (the time of enrolling group, but the intervention begins on Day 1), Day 7, Day 14, the information on gastrointestinal comfort and related behaviors is collected through the Infant Gastrointestinal Symptoms Questionnaire-13 (IGSQ-13). Information on feeding, family background, anthropometric measurements and defecation is also collected. The primary endpoint of this study is gastrointestinal comfort calculated by IGSQ-13. The secondary endpoints include crying frequency, spitting milk frequency, flatulence frequency, stool frequency and consistency score, formula acceptability and satisfaction, adverse event, etc.

• Study Type: Interventional
• Enrollment (Anticipated): 90
• Phase: Not Applicable

Contacts and Locations

Study Locations

• China
  • Shandong
    • Zibo, Shandong, China, 256499
      • Recruiting
      • Huantai Maternal and Child Health Care Hospital
      • Contact: Ying-chao Mu, BD; Phone Number: 13792199881; Email: 1319094858@qq.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 week to 6 months (CHILD)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Obtaining the informed consent of infants' parents or guardians
• Term infants (≥37 gestational weeks)
• Healthy infants aged 7-180 days
• Formula feeding or mixed feeding
• With mild gastrointestinal disorders
• Drinking the study formula more than half of the total diet daily

Exclusion Criteria:

• Adding new auxiliary food in the latest week
• Any kind of probiotics is being used
• Using drugs
• Using the formula being studied
• Having a history of milk protein allergies according to parents' reports
• Can not follow the research plans

Study Plan

How is the study designed?

Design Details

• Primary Purpose: PREVENTION
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Study formula; The infants recruited are provided with the study formula named NAN Comfort producted by Nestle Deutschland AG, Werk Biessenhofen containing moderately hydrolyzed protein and low lactose for free during study, and asked to drink the study formula more than half of the total diet daily.	Dietary supplement: Drink the study formula (NAN Comfort producted by Nestle Deutschland AG); It is same as that stated in arm description.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Infant Gastrointestinal Symptoms Questionnaire-13 (IGSQ-13) Index Score	The IGSQ-13 is a validated instrument (Riley, Trabulsi et al. 2015) consisting of 5 GI symptoms and GI-related behavioural domains. Parents (caregivers) are asked to recall specific symptoms experienced in the past week. Possible index scores range from 13 to 65; higher scores indicate higher GI burden, while lower scores indicate less GI burden.	On Day 0 (the time of enrolling group)
Infant Gastrointestinal Symptoms Questionnaire-13 (IGSQ-13) Index Score	The IGSQ-13 is a validated instrument (Riley, Trabulsi et al. 2015) consisting of 5 GI symptoms and GI-related behavioural domains. Parents (caregivers) are asked to recall specific symptoms experienced in the past week. Possible index scores range from 13 to 65; higher scores indicate higher GI burden, while lower scores indicate less GI burden.	On Day 7
Infant Gastrointestinal Symptoms Questionnaire-13 (IGSQ-13) Index Score	The IGSQ-13 is a validated instrument (Riley, Trabulsi et al. 2015) consisting of 5 GI symptoms and GI-related behavioural domains. Parents (caregivers) are asked to recall specific symptoms experienced in the past week. Possible index scores range from 13 to 65; higher scores indicate higher GI burden, while lower scores indicate less GI burden.	On Day 14

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Crying frequency	Collected by Infant Gastrointestinal Symptoms Questionnaire-13 (IGSQ-13)	On Day 0, Day 7 and Day 14
Spitting milk frequency	Collected by Infant Gastrointestinal Symptoms Questionnaire-13 (IGSQ-13)	On Day 0, Day 7 and Day 14
Flatulence frequency	Collected by Infant Gastrointestinal Symptoms Questionnaire-13 (IGSQ-13)	On Day 0, Day 7 and Day 14
Stool frequency and consistency	Collecting infants stool photos	On Day 1, Day 2 and Day 3
Formula acceptability and satisfaction	Collected by a structured questionnaire，which is designed for this study specially, including 5 questions, and will be analyzed separately for each question (no total score used).	On Day 14
Adverse event frequency	Confirmed by doctor	Day1 to Day 14

Collaborators and Investigators

• Sponsor: Peking University
• Collaborators: Huantai Maternal and Child Health Care Hospital
• Investigators: Study Chair: Jian-meng Liu, PhD, Peking University; Study Director: Ying-chao Mu, BD, Huantai Maternal and Child Health Care Hospital

Publications and helpful links

General Publications

• Huang Y, Zhou Y, Li H, Chen Y, Mu Y, Yuan A, Yang Y, Liu J. The Effects of a Partially Hydrolyzed Formula with Low Lactose and Probiotics on Mild Gastrointestinal Disorders of Infants: A Single-Armed Clinical Trial. Nutrients. 2021 Sep 25;13(10):3371. doi: 10.3390/nu13103371.

Study record dates

Study Major Dates

• Study Start (ACTUAL): October 10, 2019
• Primary Completion (ANTICIPATED): April 30, 2020
• Study Completion (ANTICIPATED): May 15, 2020

Study Registration Dates

• First Submitted: September 26, 2019
• First Submitted That Met QC Criteria: October 1, 2019
• First Posted (ACTUAL): October 2, 2019

Study Record Updates

• Last Update Posted (ACTUAL): April 2, 2020
• Last Update Submitted That Met QC Criteria: March 31, 2020
• Last Verified: March 1, 2020

More Information

Terms related to this study

• Keywords: Infant formula; Mild gastrointestinal disorders; Infant gastrointestinal symptoms questionnaire
• Additional Relevant MeSH Terms: Nutrition Disorders; Infant Nutrition Disorders
• Other Study ID Numbers: PKUFM.191010

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No